However, the clinical applicability of GLP-1R analogs to reverse obesity and improve metabolic rearrangements is suboptimal and associated with dose-limiting adverse gastrointestinal events (Meier, 2012). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.